Loading…

Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease

Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast can...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-11, Vol.15 (11), p.e49710
Main Authors: Ekram, Samar N, Al Shanbari, Nasser, Bin Laswad, Bassam M, Alharthi, Abdulrahman, Tayeb, Waseem, Bahha, Abdulbari
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73
container_end_page
container_issue 11
container_start_page e49710
container_title Curēus (Palo Alto, CA)
container_volume 15
creator Ekram, Samar N
Al Shanbari, Nasser
Bin Laswad, Bassam M
Alharthi, Abdulrahman
Tayeb, Waseem
Bahha, Abdulbari
description Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T>G, p.(Tyr212*) in the checkpoint kinase 2 ( ) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.
doi_str_mv 10.7759/cureus.49710
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2908074111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2908074111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</originalsourceid><addsrcrecordid>eNpNkMFPwjAUxhujEYPcPJsmXjRx2K6l7bzhRDBgJEbicem21zCUDtvt4Ml_3SpoTA99ef1933v9EDqhpC_lILkqWget7_NEUrKHjmIqVKSo4vv_6g7qeb8ihFAiYyLJIeowRQVVjB2hz3QJxeumrmyDp5XVHnCMz9PJaBpf4DFYwA9to5uqtriyWON5qCGwL1WzxDcOtG-wtiWeu9oHDnCqbQHuGg_xwlbvLYQX8EGx9ahN8HjSDvBt5YMYjtGB0W8eeru7ixZ3o-d0Es0ex_fpcBYVMaVNxKgiSjAtSprIxChhwBiVK8HzQgwSLss4kYYLzgtFuSHhyNAVLDZ5bkrJuuhs67txddjKN9mqbp0NI7M4IYpITikN1OWWKsJ3vAOTbVy11u4joyT7DjzbBp79BB7w051pm6-h_IN_42Vfz3d6ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2908074111</pqid></control><display><type>article</type><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><creator>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</creator><creatorcontrib>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</creatorcontrib><description>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T&gt;G, p.(Tyr212*) in the checkpoint kinase 2 ( ) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.49710</identifier><identifier>PMID: 38161833</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Breast cancer ; Case reports ; Family medical history ; Magnetic resonance imaging ; Mens health ; Mutation ; Ovarian cancer ; Prostate cancer</subject><ispartof>Curēus (Palo Alto, CA), 2023-11, Vol.15 (11), p.e49710</ispartof><rights>Copyright © 2023, Ekram et al.</rights><rights>Copyright © 2023, Ekram et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2908074111/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2908074111?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25732,27903,27904,36991,44569,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38161833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ekram, Samar N</creatorcontrib><creatorcontrib>Al Shanbari, Nasser</creatorcontrib><creatorcontrib>Bin Laswad, Bassam M</creatorcontrib><creatorcontrib>Alharthi, Abdulrahman</creatorcontrib><creatorcontrib>Tayeb, Waseem</creatorcontrib><creatorcontrib>Bahha, Abdulbari</creatorcontrib><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T&gt;G, p.(Tyr212*) in the checkpoint kinase 2 ( ) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</description><subject>Breast cancer</subject><subject>Case reports</subject><subject>Family medical history</subject><subject>Magnetic resonance imaging</subject><subject>Mens health</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Prostate cancer</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpNkMFPwjAUxhujEYPcPJsmXjRx2K6l7bzhRDBgJEbicem21zCUDtvt4Ml_3SpoTA99ef1933v9EDqhpC_lILkqWget7_NEUrKHjmIqVKSo4vv_6g7qeb8ihFAiYyLJIeowRQVVjB2hz3QJxeumrmyDp5XVHnCMz9PJaBpf4DFYwA9to5uqtriyWON5qCGwL1WzxDcOtG-wtiWeu9oHDnCqbQHuGg_xwlbvLYQX8EGx9ahN8HjSDvBt5YMYjtGB0W8eeru7ixZ3o-d0Es0ex_fpcBYVMaVNxKgiSjAtSprIxChhwBiVK8HzQgwSLss4kYYLzgtFuSHhyNAVLDZ5bkrJuuhs67txddjKN9mqbp0NI7M4IYpITikN1OWWKsJ3vAOTbVy11u4joyT7DjzbBp79BB7w051pm6-h_IN_42Vfz3d6ew</recordid><startdate>20231130</startdate><enddate>20231130</enddate><creator>Ekram, Samar N</creator><creator>Al Shanbari, Nasser</creator><creator>Bin Laswad, Bassam M</creator><creator>Alharthi, Abdulrahman</creator><creator>Tayeb, Waseem</creator><creator>Bahha, Abdulbari</creator><general>Cureus Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20231130</creationdate><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><author>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Case reports</topic><topic>Family medical history</topic><topic>Magnetic resonance imaging</topic><topic>Mens health</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ekram, Samar N</creatorcontrib><creatorcontrib>Al Shanbari, Nasser</creatorcontrib><creatorcontrib>Bin Laswad, Bassam M</creatorcontrib><creatorcontrib>Alharthi, Abdulrahman</creatorcontrib><creatorcontrib>Tayeb, Waseem</creatorcontrib><creatorcontrib>Bahha, Abdulbari</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ekram, Samar N</au><au>Al Shanbari, Nasser</au><au>Bin Laswad, Bassam M</au><au>Alharthi, Abdulrahman</au><au>Tayeb, Waseem</au><au>Bahha, Abdulbari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-11-30</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>e49710</spage><pages>e49710-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T&gt;G, p.(Tyr212*) in the checkpoint kinase 2 ( ) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38161833</pmid><doi>10.7759/cureus.49710</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2023-11, Vol.15 (11), p.e49710
issn 2168-8184
2168-8184
language eng
recordid cdi_proquest_journals_2908074111
source PMC (PubMed Central); Publicly Available Content (ProQuest)
subjects Breast cancer
Case reports
Family medical history
Magnetic resonance imaging
Mens health
Mutation
Ovarian cancer
Prostate cancer
title Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A02%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Checkpoint%20Kinase%202%20(CHEK2)%20Gene%20Mutation%20in%20a%20Patient%20With%20Breast%20and%20Prostate%20Cancer:%20A%20Unique%20Presentation%20of%20a%20Rare%20Disease&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ekram,%20Samar%20N&rft.date=2023-11-30&rft.volume=15&rft.issue=11&rft.spage=e49710&rft.pages=e49710-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.49710&rft_dat=%3Cproquest_cross%3E2908074111%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2908074111&rft_id=info:pmid/38161833&rfr_iscdi=true